CDKN2A and neoplasm: At treatment endpoint for the WM4223 in vivo study (day 50), tumor tissue was characterized by reverse-phase protein array (RPPA) to identify the mechanism(s) of action underlying the long-term therapeutic efficacy of MEKi + CDK4i/6i relative to single-agent therapy (Fig. 4E).